SHANK2 and oropharynx cancer: Several studies noted SHANK2’s amplification in esophageal and oropharyngeal cancer and its association with poor prognosis (Carneiro et al., 2008; Qin et al., 2016; Barros-Filho et al., 2018; Yu et al., 2019; Brown et al., 2020).